Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Celgene Pays Big For Antisense Drug
by Michael McCoy
April 28, 2014
| A version of this story appeared in
Volume 92, Issue 17
Celgene has agreed to pay $710 million to Ireland’s Nogra Pharma to license GED-0301, an oral antisense DNA oligonucleotide being developed for the treatment of Crohn’s disease. The drug works by shutting down messenger RNA that encodes for a protein, Smad7, involved in inflammation. On the basis of the results of a Phase II clinical trial, Celgene plans to initiate a Phase III program by the end of the year. If the drug is approved and successful, milestone payments to Nogra could reach $1.8 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter